van't Veer M B
Department of Hematology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Ann Hematol. 1992 Apr;64(4):161-5. doi: 10.1007/BF01696217.
A small group of acute leukemias can be classified by morphological, cytochemical, or immunological marker analysis neither as acute lymphatic leukemia nor as acute myeloid leukemia. These leukemias are referred to as acute undifferentiated leukemia (AUL) and make up 2%-7% of the acute nonmyeloid leukemias. These leukemias are poorly defined in the literature and are also sometimes referred to as AML-MO. Most of the definitions include in the morphological and cytochemical criteria the expression of myeloid antigens. Here the value of these markers and of other techniques used in the diagnosis of undifferentiated or minimally differentiated leukemia is discussed. More than half of the leukemias that are undifferentiated by morphology and cytochemistry on the light-microscopic level show a positive reaction for myeloperoxidase by electron microscopy, which points to an early myeloid differentiation of those leukemias. Immunological marker analysis in most cases is inconclusive. Most show a positive reaction for CD 13, CD 33 or other myeloid-associated markers. However, in about half of these leukemias co-expression of lymphatic markers is seen. In a small minority, only lymphatic markers are expressed. Cytogenetic abnormalities which are found in these leukemias vary in type, and antigen receptor rearrangements are not lineage specific. Receptor studies, gene expression, and in vitro culture studies may, in the near future, contribute substantially to our knowledge about the commitment of these undifferentiated or minimally differentiated blasts. Recent definitions for AUL and AML-MO based on these different techniques are discussed.
一小部分急性白血病,通过形态学、细胞化学或免疫标记分析,既不能归类为急性淋巴细胞白血病,也不能归类为急性髓细胞白血病。这些白血病被称为急性未分化白血病(AUL),占急性非髓细胞白血病的2%-7%。这些白血病在文献中定义不明确,有时也被称为AML-MO。大多数定义在形态学和细胞化学标准中纳入了髓系抗原的表达。本文讨论了这些标记物以及用于诊断未分化或低分化白血病的其他技术的价值。超过半数在光镜水平上形态学和细胞化学未分化的白血病,在电镜下显示髓过氧化物酶呈阳性反应,这表明这些白血病存在早期髓系分化。大多数情况下,免疫标记分析尚无定论。大多数病例对CD13、CD33或其他髓系相关标记物呈阳性反应。然而,在大约半数的这些白血病中可见淋巴系标记物的共表达。少数病例仅表达淋巴系标记物。这些白血病中发现的细胞遗传学异常类型各异,抗原受体重排不具有谱系特异性。受体研究、基因表达和体外培养研究可能在不久的将来,极大地增进我们对这些未分化或低分化原始细胞分化的了解。本文讨论了基于这些不同技术的AUL和AML-MO的最新定义。